A clinical trial registration update dated July 9, 2026 lists a study titled "Study on Neostigmine Acupoint Injection at Zusanli(ST36) for Treating Mechanical Ventilation-Associated Gastrointestinal Dysfunction," identified as NCT07692282. The trial phase is listed as not applicable. Its current status is not yet recruiting, meaning participant enrollment has not begun as of the date recorded.
This registration is part of ongoing research tracking related to vasoactive intestinal peptide, a compound with approved regulatory status. No results, outcomes, or efficacy data have been posted for this trial at this stage. The registry entry reflects only the study's planned design and current recruitment status, not any findings.
Readers should note that a "not yet recruiting" status indicates the trial has been registered but has not started accepting participants. Further updates would be expected as the study progresses through recruitment and subsequent phases, if applicable. No additional details about study design, eligibility, or timeline were included in this update beyond the title, identifier, phase designation, and status.
For more background on vasoactive intestinal peptide, including its approved regulatory status and general context, readers can consult the compound overview.